

Is chemo right for you? Only one genomic test can predict its benefit.

Why Did My Doctor Order This Test?

When it comes to treatment decisions for your invasive breast cancer, the Oncotype DX Breast Recurrence Score® test can help you and your doctor understand which treatment options are right for you. Not everyone with early-stage breast cancer benefits from chemotherapy. The Oncotype DX Breast Recurrence Score test is the only test that has been proven to predict the benefit of chemotherapy. It will also identify how likely your cancer is to return. Because every patient's breast cancer is unique, understanding your tumor's biology will help you and your doctor personalize your treatment plan.

Genomic Testing – The Key to Knowing Your Cancer

Unlike a genetic test which assesses your hereditary risk for cancer, a genomic test analyzes cancer tissue to provide information on how a tumor might behave. It identifies changes in DNA that may be driving the growth of your tumor. By providing vital information such as how likely your cancer is to recur or how it may respond to chemotherapy, genomic testing can help you and your doctor select an appropriate treatment course.

Groundbreaking Research

With the results of the TAILORx and RxPONDER trials in the *New England Journal of Medicine*, the Oncotype DX Breast Recurrence Score test can now be used to determine with precision the benefit of chemotherapy for both node-negative and node-positive early-stage breast cancer patients.¹

1 - Kalinsky K, et al. *New Engl J Med*. 2021. Sparano et al. *N Engl J Med*. 2015/2018.



Nina S.
Oncotype DX Breast
Recurrence Score®
patient. Navigating
breast cancer
since 2021.

How Does it Work?


	1. The tissue from your most recent biopsy or lumpectomy is sent to our lab for analysis. No additional procedures are required.
	2. Test results are sent to your doctor.
	3. You and your doctor review the results together.

oncotype dx®
Breast Recurrence Score

by EXACT SCIENCES

What Can I Expect from My Test Results?

Your results are reported as a Recurrence Score® result based on a scale of 0-100. A lower Recurrence Score result means your cancer is less likely to come back in the next 9 years if treated with hormonal therapy alone, so chemotherapy is less likely to benefit you. A higher Recurrence Score result means your cancer could potentially come back in the next 9 years so you may benefit from chemotherapy. Make sure to ask your doctor for your test results and to review them with you.



How likely am I to benefit from chemotherapy?

Your Recurrence Score result can help you and your doctor determine if chemotherapy is necessary.

How likely is it that my cancer will come back?

Your test result can indicate the likelihood that your cancer will recur in the next 9 years if treated with hormone therapy alone.

Used by over 1 million patients,[†] the Oncotype DX Breast Recurrence Score test is the only test that has been proven to predict the benefit of chemotherapy.^{††}

† - Data on file.

†† - Albain Lancet Oncol 2010 and Paik S, et al. J Clin Oncol. 2006

"I was not familiar with genomic testing before I took the Oncotype DX test. When I received my score of 21 and I was told I could avoid chemotherapy, for the first time since my diagnosis, I got emotional."

*Nina S.,
Oncotype DX Breast
Recurrence Score
test patient*

If you would like to share your story with other patients about your experience with the Oncotype DX Breast Recurrence Score test, please contact us at: patientstories@exactsciences.com.

Learn More About Your Insurance Options

86% of Oncotype DX Breast Recurrence Score test patients have \$0 financial responsibility.*

To learn about Medicare coverage, private insurance coverage and financial assistance, contact our Customer Service group by phone at:

888-ONCOTYPE (888-662-6897) – select option 2

or by email at:

oncotype@exactsciences.com.

Exact Sciences offers financial assistance for eligible patients. If eligible, both insured and uninsured patients will have no out-of-pocket costs.



Scan here to see if you're eligible for testing at no cost, or visit: **ExactSciencesPO.com/assistance** for more information.

EXACT SCIENCES

*The number cited is based on historical patient billing data from 1/2/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about the Oncotype DX Breast Recurrence Score test coverage.

Oncotype DX, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, and Recurrence Score are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. ©2022 Genomic Health, Inc. All rights reserved. M-US-IBC-00720.

This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Talk to your health care provider about such matters and whether the Oncotype DX Breast Recurrence Score test may be right for you. The actual patients shown here used the Oncotype DX Breast Recurrence Score test in making their treatment decisions with their physicians. Individual results may vary.